Your browser doesn't support javascript.
Robust SARS-CoV-2 T cell responses with common TCRαß motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells.
Nguyen, Thi H O; Rowntree, Louise C; Allen, Lilith F; Chua, Brendon Y; Kedzierski, Lukasz; Lim, Chhay; Lasica, Masa; Tennakoon, G Surekha; Saunders, Natalie R; Crane, Megan; Chee, Lynette; Seymour, John F; Anderson, Mary Ann; Whitechurch, Ashley; Clemens, E Bridie; Zhang, Wuji; Chang, So Young; Habel, Jennifer R; Jia, Xiaoxiao; McQuilten, Hayley A; Minervina, Anastasia A; Pogorelyy, Mikhail V; Chaurasia, Priyanka; Petersen, Jan; Menon, Tejas; Hensen, Luca; Neil, Jessica A; Mordant, Francesca L; Tan, Hyon-Xhi; Cabug, Aira F; Wheatley, Adam K; Kent, Stephen J; Subbarao, Kanta; Karapanagiotidis, Theo; Huang, Han; Vo, Lynn K; Cain, Natalie L; Nicholson, Suellen; Krammer, Florian; Gibney, Grace; James, Fiona; Trevillyan, Janine M; Trubiano, Jason A; Mitchell, Jeni; Christensen, Britt; Bond, Katherine A; Williamson, Deborah A; Rossjohn, Jamie; Crawford, Jeremy Chase; Thomas, Paul G.
  • Nguyen THO; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Rowntree LC; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Allen LF; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Chua BY; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Hok
  • Kedzierski L; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia; Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Melbourne, VIC 3000, Australia.
  • Lim C; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Lasica M; Department of Haematology, St Vincent's Hospital, Fitzroy, VIC 3065, Australia; Department of Haematology, Eastern Health, Box Hill, VIC 3128, Australia.
  • Tennakoon GS; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Saunders NR; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Crane M; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Chee L; Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia.
  • Seymour JF; Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.
  • Anderson MA; Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC
  • Whitechurch A; Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Clemens EB; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Zhang W; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Chang SY; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Habel JR; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Jia X; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • McQuilten HA; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Minervina AA; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Pogorelyy MV; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Chaurasia P; Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
  • Petersen J; Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
  • Menon T; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Hensen L; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Neil JA; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Mordant FL; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Tan HX; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Cabug AF; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Wheatley AK; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Kent SJ; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Melbourne, VIC 3010, Australia; Melbourne Se
  • Subbarao K; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia; World Health Organisation (WHO) Collaborating Centre for Reference and Research on Influenza, at The Peter Doherty Institute for Infection an
  • Karapanagiotidis T; Victorian Infectious Diseases Reference Laboratory (VIDRL), at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Huang H; Victorian Infectious Diseases Reference Laboratory (VIDRL), at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Vo LK; Victorian Infectious Diseases Reference Laboratory (VIDRL), at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Cain NL; Victorian Infectious Diseases Reference Laboratory (VIDRL), at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Nicholson S; Victorian Infectious Diseases Reference Laboratory (VIDRL), at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Krammer F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Gibney G; Department of Infectious Diseases, Austin Health, Heidelberg, VIC 3084, Australia.
  • James F; Department of Infectious Diseases, Austin Health, Heidelberg, VIC 3084, Australia.
  • Trevillyan JM; Department of Infectious Diseases, Austin Health, Heidelberg, VIC 3084, Australia; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Trubiano JA; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia; Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, VIC 3084, Austr
  • Mitchell J; Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia.
  • Christensen B; Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia; Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia.
  • Bond KA; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia; Victorian Infectious Diseases Reference Laboratory (VIDRL), at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, A
  • Williamson DA; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Victorian Infectious Diseases Reference Laboratory (VIDRL), at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia; Department of Infectious Diseases, University of Melbourne at th
  • Rossjohn J; Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia; Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, CF14 4XN Cardiff, UK.
  • Crawford JC; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Thomas PG; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Cell Rep Med ; 4(4): 101017, 2023 04 18.
Article in English | MEDLINE | ID: covidwho-2300905
ABSTRACT
Immunocompromised hematology patients are vulnerable to severe COVID-19 and respond poorly to vaccination. Relative deficits in immunity are, however, unclear, especially after 3 vaccine doses. We evaluated immune responses in hematology patients across three COVID-19 vaccination doses. Seropositivity was low after a first dose of BNT162b2 and ChAdOx1 (∼26%), increased to 59%-75% after a second dose, and increased to 85% after a third dose. While prototypical antibody-secreting cells (ASCs) and T follicular helper (Tfh) cell responses were elicited in healthy participants, hematology patients showed prolonged ASCs and skewed Tfh2/17 responses. Importantly, vaccine-induced expansions of spike-specific and peptide-HLA tetramer-specific CD4+/CD8+ T cells, together with their T cell receptor (TCR) repertoires, were robust in hematology patients, irrespective of B cell numbers, and comparable to healthy participants. Vaccinated patients with breakthrough infections developed higher antibody responses, while T cell responses were comparable to healthy groups. COVID-19 vaccination induces robust T cell immunity in hematology patients of varying diseases and treatments irrespective of B cell numbers and antibody response.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Cell Rep Med Year: 2023 Document Type: Article Affiliation country: J.xcrm.2023.101017

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Cell Rep Med Year: 2023 Document Type: Article Affiliation country: J.xcrm.2023.101017